⏱️10min read | Roche's decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn't end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials.

⏱️ 8 min read | July was a hard month for Huntington's disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD.

⏱️10 min read | Four years after announcing positive results in their trial of ANX005 (tanruprubart) for HD, Annexon has formally published the results. It’s safe, hits its target, and may have helped some participants – so what’s the holdup?